MicroPort® Lifesciences Attends Diabetes and Gonadal Disorders Meeting to Promote La Fenice®

Shanghai, China – 8 July, 2015 - Shanghai MicroPort Lifesciences Co ("MicroPort® Lifesciences") recently attended the Fifth Academic Meeting of Diabetes and Gonadal Disorders of Chinese Medical Association, held from July 2 to July 4 in Chengdu of Sichuan Province. The meeting provides a platform for experts of diabetes and gonadal disorders to share the latest developments in the two areas. MicroPort® Lifesciences was present with a booth and released reports to promote our endocrinal management device La Fenice® Hypophyseal Hormone Infusion Pump ("La Fenice®").
In-house developed by MicroPort® Lifesciences, La Fenice® is designed for the treatment of Idiopathic Hypogonadotropic Hypogonadism ("IHH") which is also known as Kallmann Syndrome and is the first domestically developed gonadotropin-releasing hormone ("GnRH") pulse pump. In China, the incidence of IHH is 1/2000 in men and 1/10000 in women.
During the meeting, Professor Jingtao Dou from Chinese PLA General Hospital was invited to interpret the report "IHH Treatment Expert Consensus" which is compiled by professionals of the Gonad Research Group of Chinese Medical Association to the more than 600 doctors in attendance. This report is expected to enhance endocrinologists' understandings in IHH diagnosis and treatment, as well as provide guidelines on La Fenice®'s application.
Meanwhile, MicroPort® Lifescience organized a discussion among several endocrinologists from famous domestic hospitals including Chinese PLA General Hospital, Peking Union Medical College Hospital and the First Affiliated Hospital of Zhengzhou University. During the discussion, Professor Xueyan Wu of Peking Union Medical College Hospital shared his hospital's experience in treating IHH with La Fenice®. He compared the effects and influence factors of improving sperm-producing when male patients are respectively treated with La Fenice® and HCG/HMG intramuscular injection, as well as the effects and influence factors of increasing ovulation when female patients are treated with La Fenice® and HCG/HMG intramuscular injection respectively, and reached the conclusion that La Fenice® can awake the pituitary function but HCG/HMG intramuscular injection produced no effect.
La Fenice® works as an artificial hypothalamus – La Fenice® stimulates hypophysis to excrete follicle-stimulating hormone ("FSH") and luteinizing hormone ("LH") by simulating pulse excretion of human GnRH. In this way, it helps the development of the patient's secondary sex characters and enables him/her to regain sexuality and fertility.